Isolere Bio

Isolere Bio is a private, early-revenue stage company providing a platform technology for purifying biologics. Its IsoTag™ reagents use a novel mechanism combining affinity binding and liquid-liquid phase separation to capture, concentrate, and purify targets like AAV and lentiviral vectors directly in solution, bypassing traditional chromatography. Acquired by filtration leader Donaldson in 2023, Isolere now operates as part of Donaldson's Life Sciences division, aiming to address critical bottlenecks in bioprocessing for gene therapy manufacturing. The company offers evaluation kits and is actively collaborating with partners to integrate its scalable purification solutions.

IsoTag™ Reagent Technology combining affinity ligands with tunable liquid-liquid phase separation for chromatography-free purification of biologics.

Isolere competes with dominant chromatography resin suppliers (Cytiva, Sartorius, Thermo Fisher) and providers of membrane adsorbers. Its key differentiation is the novel mechanism of action (affinity + phase separation) enabling rapid, column-free processing. Other startups are exploring alternative purification methods, but Isolere's acquisition by Donaldson provides a unique commercial and manufacturing advantage.